Japan · Delayed Price · Currency is JPY Lion Corporation Earnings Call Transcripts
Fiscal Year 2026
-
9M sales and core operating income grew, with premium Oral Care mix, efficiency and overseas recovery offsetting higher costs. Full-year guidance is unchanged; a ¥20bn buyback and ¥34 annual dividend were announced.
-
Sales and profit exceeded expectations in Q2 FY2026, driven by strong Oral Healthcare growth in Japan and recovery in overseas markets. Despite a significant increase in raw material costs, management remains confident in achieving full-year targets through price hikes and cost controls.
-
Strong market positions in Asia are being leveraged through a glocalization strategy, prioritizing high value-added oral healthcare and expanding into beauty care and pharmaceuticals. Organizational restructuring and local leadership drive rapid, profitable growth and adaptation to evolving consumer needs.
-
Q1 saw solid sales and profit growth, led by oral healthcare and overseas integration, with margins improving. Despite JPY 3-4 billion in expected cost increases from Middle East risks, full-year targets and dividend guidance remain unchanged, supported by proactive countermeasures.
Fiscal Year 2025
-
Revenue and profit exceeded guidance for FY 2025, driven by high value-added products and overseas growth. FY 2026 targets further margin expansion, with strong capital allocation to oral healthcare and continued dividend increases.
-
Sales and profit rose year-on-year, with Q3 growth driven by new products and a profitable Vietnam subsidiary. Overseas markets face challenges, but profitability is prioritized over volume, and the full-year outlook remains unchanged.
-
Revenue and profitability improved year-on-year, driven by structural reforms, high value-added products, and cost efficiencies. Growth in Southeast Asia and premium oral care offset challenges in China and South Korea, with full-year guidance unchanged.
Fiscal Year 2024
-
Sales and profits rose for the first time in four years, driven by strong overseas growth and profit structure reforms. The company targets an EBITDA margin of over 13% by 2027, with continued focus on oral healthcare and overseas expansion.
-
Net sales and profits rose year-on-year in Q3, with core operating income exceeding expectations due to structural reforms and cost reductions. Despite a JPY 6.2 billion impairment loss, the full-year outlook is unchanged, and profitability improvements are expected from ongoing reforms and price revisions.
-
Sales and profit rose year-on-year, led by overseas growth and price increases, with core operating income and EBITDA margins improving. Portfolio reforms and SKU reductions are underway, while dividend and return policies remain robust.